Early-phase study of IMP9064 for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent.
- Your cancer must be a confirmed solid tumor that is advanced and has not responded to standard treatment (or there is no standard option).
- Your health status should be fairly good (ECOG 0–1).
- You must be able to provide tumor samples for testing.
- You must have enough time to participate (life expectancy of at least 12 weeks, as the study doctor decides).
- You must be willing to follow study visits and procedures (and possibly extra blood/tissue sampling).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new oral drug called ISM5939 for people with advanced solid tumors that haven't responded to or can't use standard treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.